ReviewAsian journal of pharmaceutical sciences2025
Advances in plant-derived vesicle like nanoparticles-based therapies for inflammatory diseases.
Review in Asian journal of pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Extracellular Vesicles Derived fromNanomaterials (Basel, Switzerland) · 2026Article
- Engineered Extracellular Vesicles for Treatment of Inflammatory Diseases.Molecular biotechnology · 2026Review
- Plant-derived nanocarriers & nanostructures for barrier-defined translation: a comprehensive review of mechanisms, targets, and translation.Journal of nanobiotechnology · 2026Review
- Plant-Based Nano-Delivery Systems in the Treatment of Inflammatory Disorders.Pharmaceutics · 2026Review
- Molecular mechanisms and translational potential of plant-derived nanovesicles in skin care and regeneration.Frontiers in cell and developmental biology · 2026Review
- Harnessing plant-derived extracellular vesicles in advanced biomaterials: from structural scaffolds to responsive systems for next-generation wound therapeutics.Burns & trauma · 2026Review
- Precision immunomodulation of viral myocarditis: a spatiotemporal intervention paradigm based on smart biomaterials.Frontiers in immunology · 2026Review
- Rethinking delivery routes: oral administration of plant-derived exosome-like nanovesicles reduces the toxicity of intravenous injection.Extracellular vesicles and circulating nucleic acids · 2026Article
- Plant-Derived Extracellular-Vesicle-Like Particles: Immune Regulation and Disease Therapy.Research (Washington, D.C.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysregulated inflammatory reactions can result in detrimental effects to the body, thereby causing various diseases. Traditional treatments relying on anti-inflammatory drugs or nanoformulations often undermine the body's physiological immune functions or potentially exhibit biotoxicity. Extracellular vesicles, which contain a diverse array of anti-inflammatory substances and possess nanomedicine transport properties, are emerging as highly promising candidates for next-generation drug delivery systems and active biological agents. Plant-derived vesicle-like nanoparticles (PDVLNs) are nanostructured particles isolated from plants. Given their wide availability and low immunogenicity, PDVLNs are considered to hold great potential in the treatment of inflammatory diseases (IDs). In this review, we introduce the principle, design consideration and treatment mechanism associated with PDVLNs in treating various IDs. Specifically, the natural ingredients carried by PDVLNs not only help eliminate danger signals such as reactive oxygen species and reactive nitrogen species, but also hinder the initiation of inflammatory responses through various mechanisms. Moreover, engineered PDVLNs nanotechnology has been successfully employed in the treatment of IDs. Finally, the review discusses the current opportunities and challenges in this field and provides insights for the future clinical applications of PDVLNs in treating IDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.